3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
32
fludarabine phosphate
25
Peripheral Blood Stem Cell Transplantation
25
Busulfan
20
Antilymphocyte Serum
19
Tacrolimus
15
Mycophenolic Acid
15
Filgrastim
15
Cyclosporine
15
Methotrexate
14
Melphalan
12
Etoposide
12
pembrolizumab
11
Whole-Body Irradiation
10
Radiotherapy
10
Methylprednisolone
10
Sirolimus
9
Psychiatric Rehabilitation
8
Nivolumab
8
Bortezomib
8
fludarabine
7
Prednisone
7
Flow Cytometry
7
sargramostim
6
romidepsin
6
Vorinostat
6
Gemcitabine
6
Doxorubicin
6
Cord Blood Stem Cell Transplantation
6
aldesleukin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma
×
cobomarsen
×
Dermatologic
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled